Solabia Acquires SEQENS Botanical & IVD Units

Solabia Group, a prominent player in natural active ingredients, has significantly expanded its capabilities through the acquisition of the Botanical Actives and In Vitro Diagnostics (IVD) divisions from SEQENS. This strategic move, supported by private equity firm Astorg, solidifies Solabia's standing as a premier provider of scientifically validated botanical components for the cosmetics industry.

The integration of SEQENS' Limoges, France-based manufacturing site brings advanced botanical extraction technologies and high-caliber production expertise into the Solabia fold. This facility's specialization in crafting natural cosmetic ingredients and diagnostic solutions aligns perfectly with Solabia's existing operational strengths, promising enhanced product development and supply chain resilience.

This acquisition follows closely on the heels of Solabia's recent purchase of Mibelle Biochemistry and the subsequent acquisition of Xebios Diagnostics Group, marking a period of aggressive expansion for the company. These three transactions within a two-month span underscore Solabia's ambition to consolidate its market leadership across multiple high-growth sectors.

The global market for cosmetic active ingredients is projected to experience robust growth, driven by increasing consumer demand for natural, sustainable, and efficacy-backed products. Industry analysts estimate the market to reach tens of billions of dollars in the coming years, with botanical extracts representing a substantial and expanding segment. Solabia's strategic acquisitions position it to capitalize on this trend, offering a comprehensive portfolio that meets evolving market needs.

SEQENS, a diversified pharmaceutical and specialty ingredients company, views this divestiture as a strategic pivot, allowing it to concentrate on its core Pharmaceutical Solutions and select Specialty Ingredients businesses. This refocusing aligns with SEQENS' long-term strategic objectives, as articulated by CEO Pascal Villemagne. The transaction's financial terms were not publicly disclosed.

Jean-Baptiste Dellon, CEO of Solabia, emphasized the synergistic nature of the deal, stating that the combined entities will fortify their market presence, secure vital supply chains, and deliver more innovative and comprehensive solutions to their clientele. The integration is expected to unlock new avenues for research and development, particularly in the burgeoning field of personalized cosmetics and advanced diagnostics.

Solabia, established in 1972, operates an extensive network of 11 production facilities and multiple R&D centers worldwide. Its vertically integrated model spans cosmetics, nutraceuticals, pharmaceuticals, biotechnology, and microbiology, including the production of culture media and detection kits. The addition of the SEQENS assets further enhances its global footprint and technological capabilities.